ABSTRACT
Hypertension is a global public health problem and causes target organ damage. It may cause an increase in mortality and morbidity due to the target organ damage it causes. Although it is sometimes difficult to regulate blood pressure in HT treatment, patients often do not respond to monotherapy, so double or triple combination therapy is needed can be heard. In this case, the effect of combination therapy in a hypertensive patient with coronary artery disease is presented.
References
1Aydoğdu S, Güler K, Bayram F, Altun B, Derici Ü, Abacı A, et al. Türk Hipertansiyon Uzlaşı Raporu 2019 [2019 Turkish Hypertension Consensus Report]. Turk Kardiyol Dern Ars 2019;47(6):535-546.
2Cuspidi C, Ambrosioni E, Mancia G, Pessina AC, Trimarco B, Zanchetti A, et al. Role of echocardiography and carotid ultrasonography in stratifying risk in patients with essential hypertension: the Assessment of Prognostic Risk Observational Survey. J Hypertens 2002;20(7):1307-1314.
3Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J 2018;39(33):3021-3104.
4Akizuki O, Inayoshi A, Kitayama T, Yao K, Shirakura S, Sasaki K, et al. Blockade of T-type voltage-dependent Ca2+ channels by benidipine, a dihydropyridine calcium channel blocker, inhibits aldosterone production in human adrenocortical cell line NCI-H295R. Eur J Pharmacol 2008;584(2-3):424-434.
5Canbolat S, Nurullahoğlu Atalık KE. Pleiotropic Effects of Calcium Channel Blockers. Kafkas J Med Sci 2019;9(2):125-131.
6Tomino Y. Renoprotective effects of the L-/T-type calcium channel blocker benidipine in patients with hypertension. Curr Hypertens Rev 2013;9(2):108-114.
7Ohishi M, Takagi T, Ito N, Terai M, Tatara Y, Hayashi N, et al. Renal-protective effect of T-and L-type calcium channel blockers in hypertensive patients: an Amlodipine-to-Benidipine Changeover (ABC) study. Hypertens Res 2007;30(9):797-806.
8Inoue S, Tomino Y. Effects of calcium antagonists in hypertensive patients with renal dysfunction: a prospective, randomized, parallel trial comparing benidipine and nifedipine. Nephrology (Carlton) 2004;9(5):265-271.
9Kitakaze M, Karasawa A, Kobayashi H, Tanaka H, Kuzuya T, Hori M. Benidipine: A New Ca2+ Channel Blocker with a Cardioprotective Effect. Cardiovascular Drug Reviews 1999;17(1):1-15.
10Umemoto S, Ogihara T, Matsuzaki M, Rakugi H, Ohashi Y, Saruta T, et al. Effects of calcium channel blocker benidipine-based combination therapy on target blood pressure control and cardiovascular outcome: a sub-analysis of the COPE trial. Hypertens Res 2017;40(4):376-384.
